{"filing":{"accession_number":"0001104659-26-070966","cik":"0000894158","ticker":"TOVX","company_name":"Theriva Biologics, Inc.","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"tm2616886d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/894158/000110465926070966/tm2616886d1_8k.htm"},"events":[{"id":6409,"run_id":5614,"accession_number":"0001104659-26-070966","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"summary":"The filing discloses a warrant inducement agreement requiring stockholder approval for the issuance of up to 16,184,560 shares of common stock upon warrant exercise. Although the Special Meeting failed to achieve quorum, the core material event is the company's obligation to seek approval for a substantial dilutive issuance of equity securities to institutional investors under the October 16, 2025 Inducement Agreement. This represents a material capital structure event affecting existing shareholders.","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-06-05","form":"8-K","submitted_at":null,"items":[{"id":4765,"accession_number":"0001104659-26-070966","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a warrant inducement agreement requiring stockholder approval for the issuance of up to 16,184,560 shares of common stock upon warrant exercise. Although the Special Meeting failed to achieve quorum, the core material event is the company's obligation to seek approval for a substantial dilutive issuance of equity securities to institutional investors under the October 16, 2025 Inducement Agreement. This represents a material capital structure event affecting existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:08:39.670283+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4765,"accession_number":"0001104659-26-070966","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses a warrant inducement agreement requiring stockholder approval for the issuance of up to 16,184,560 shares of common stock upon warrant exercise. Although the Special Meeting failed to achieve quorum, the core material event is the company's obligation to seek approval for a substantial dilutive issuance of equity securities to institutional investors under the October 16, 2025 Inducement Agreement. This represents a material capital structure event affecting existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:08:39.670283+00:00","company_name":"Theriva Biologics, Inc.","ticker":"TOVX","filing_date":"2026-06-05"}]}